Idec Zevalin Imaging Step Added For Safety; July Response To FDA Planned
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s request that Idec add an imaging step to the commercial protocol for its radioimmunotherapy Zevalin (ibritumomab tiuxetan) is intended to enhance safety of the product, the company indicated during a May 10 conference call.